Unveiling 18 Analyst Insights On Blueprint Medicines
Ratings for Blueprint Medicines (NASDAQ:BPMC) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 5 | 3 | 0 | 2 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 7 | 2 | 3 | 0 | 1 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 1 |
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $111.06, a high estimate of $168.00, and a low estimate of $65.00. Surpassing the previous average price target of $89.40, the current average has increased by 24.23%.
Deciphering Analyst Ratings: An In-Depth Analysis
The analysis of recent analyst actions sheds light on the perception of Blueprint Medicines by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Sudan Loganathan | Stephens & Co. | Announces | Overweight | $140.00 | - |
| Andrew Berens | Leerink Partners | Raises | Market Perform | $97.00 | $50.00 |
| Terence Flynn | Goldman Sachs | Raises | Buy | $168.00 | $121.00 |
| David Lebowitz | Citigroup | Raises | Sell | $76.00 | $65.00 |
| Andrew Fein | HC Wainwright & Co. | Raises | Buy | $135.00 | $125.00 |
| Reni Benjamin | JMP Securities | Raises | Market Outperform | $125.00 | $114.00 |
| Peter Lawson | Barclays | Raises | Equal-Weight | $75.00 | $70.00 |
| Christopher Raymond | Piper Sandler | Raises | Neutral | $104.00 | $78.00 |
| Ami Fadia | Needham | Raises | Buy | $130.00 | $97.00 |
| Ami Fadia | Needham | Maintains | Buy | $97.00 | - |
| Bradley Canino | Stifel | Raises | Buy | $130.00 | $120.00 |
| David Nierengarten | Wedbush | Maintains | Outperform | $110.00 | - |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $125.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $97.00 | - |
| Reni Benjamin | JMP Securities | Maintains | Market Outperform | $114.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $97.00 | - |
| Reni Benjamin | JMP Securities | Maintains | Market Outperform | $114.00 | - |
| David Lebowitz | Citigroup | Raises | Sell | $65.00 | $54.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Blueprint Medicines. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Blueprint Medicines compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Blueprint Medicines's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Blueprint Medicines's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Blueprint Medicines analyst ratings.
Unveiling the Story Behind Blueprint Medicines
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
A Deep Dive into Blueprint Medicines's Financials
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Blueprint Medicines's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 51.87%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Blueprint Medicines's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 92.74%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Blueprint Medicines's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 40.4% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Blueprint Medicines's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 8.54%, the company showcases efficient use of assets and strong financial health.
Debt Management: Blueprint Medicines's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.06.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.